PhdFit
Resume-aware faculty matching

Find professors who actually fit you

Review faculty evidence in public, then use the workspace to turn your background into a shortlist, outreach, and meeting prep.

Profile-awarePaper evidenceSix agents
Marc Breton

Marc Breton

· Associate Director of Research, Center for Diabetes Technology, School of Medicine Professor, School of Medicine

University of Virginia · Systems and Information Engineering

Active 1994–2026

h-index47
Citations9.1k
Papers262124 last 5y
Funding$54.1M2 active

Academic metrics are sourced from OpenAlex and public funding records; values may differ from Google Scholar.

Faculty page
See your match with Marc Breton — sign in to PhdFit.Sign in

About

Dr. Marc Breton’s research is centered on bringing engineering techniques such as mathematical modeling, simulation, signal processing, and automatic control into the field of medicine and clinical practice. He has participated in the design of the first (and to date only) simulation environment accepted by the US Food & Drugs Administration as a replacement for animal studies in pre-clinical assessment of insulin treatment strategies, and is now in charge of its update and further development. He has been principal investigator on many clinical trials aimed at testing new insulin delivery strategies capable of avoiding hypoglycemia and reducing hyperglycemia, using continuous glucose monitors and subcutaneous insulin injection (Artificial Pancreas), and participated in the protocol and system designs.

Research topics

  • Medicine
  • Endocrinology
  • Internal medicine
  • Mathematics
  • Computer Science
  • Artificial Intelligence
  • Pediatrics
  • Control engineering
  • Intensive care medicine
  • Statistics

Selected publications

  • A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes

    New England Journal of Medicine · 2020 · 424 citations

    1st authorCorresponding

    BACKGROUND: A closed-loop system of insulin delivery (also called an artificial pancreas) may improve glycemic outcomes in children with type 1 diabetes. METHODS: In a 16-week, multicenter, randomized, open-label, parallel-group trial, we assigned, in a 3:1 ratio, children 6 to 13 years of age who had type 1 diabetes to receive treatment with the use of either a closed-loop system of insulin delivery (closed-loop group) or a sensor-augmented insulin pump (control group). The primary outcome was…

    DOI

  • Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice

    Endocrine Reviews · 2022 · 387 citations

    The significant and growing global prevalence of diabetes continues to challenge people with diabetes (PwD), healthcare providers, and payers. While maintaining near-normal glucose levels has been shown to prevent or delay the progression of the long-term complications of diabetes, a significant proportion of PwD are not attaining their glycemic goals. During the past 6 years, we have seen tremendous advances in automated insulin delivery (AID) technologies. Numerous randomized controlled trials…

    DOI

  • A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings

    Journal of Diabetes Science and Technology · 2022 · 268 citations

    BACKGROUND: A composite metric for the quality of glycemia from continuous glucose monitor (CGM) tracings could be useful for assisting with basic clinical interpretation of CGM data. METHODS: We assembled a data set of 14-day CGM tracings from 225 insulin-treated adults with diabetes. Using a balanced incomplete block design, 330 clinicians who were highly experienced with CGM analysis and interpretation ranked the CGM tracings from best to worst quality of glycemia. We used principal component…

    DOI

  • One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology

    Diabetes Technology & Therapeutics · 2021 · 239 citations

    1st authorCorresponding

    In this real-world use analysis, Control-IQ technology retained, and to some extent exceeded, the results obtained in randomized controlled trials, showing glycemic improvements in a broad age range of people with different types of diabetes.

    DOI

  • Artificial Intelligence in Diabetes Care: Applications, Challenges, and Opportunities Ahead

    Endocrine Practice · 2025-07-17 · 11 citations

    reviewOpen access
    PublisherOA PDFDOI

Recent grants

Frequent coauthors

  • Bruce A. Buckingham

    Stanford University

    150 shared

  • Gregory P. Forlenza

    University of Colorado Anschutz Medical Campus

    136 shared

  • Roy W. Beck

    Jaeb Center for Health Research

    133 shared

  • Daniel R. Cherñavvsky

    130 shared

  • Mary C. Oliveri

    University of Virginia

    125 shared

  • Boris Kovatchev

    122 shared

  • Emma Emory

    116 shared

  • Craig Kollman

    Emory University

    116 shared

Similar researchers at University of Virginia

  • Resume-aware match score
  • Save to shortlist
  • AI-drafted outreach

See your match with Marc Breton

PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.

Sign in to PhdFitHow it works
  • Free to start
  • No credit card
  • 30-second signup